[go: up one dir, main page]

WO2001089514A3 - Ameliorations apportees en matiere de survie - Google Patents

Ameliorations apportees en matiere de survie Download PDF

Info

Publication number
WO2001089514A3
WO2001089514A3 PCT/GB2001/002267 GB0102267W WO0189514A3 WO 2001089514 A3 WO2001089514 A3 WO 2001089514A3 GB 0102267 W GB0102267 W GB 0102267W WO 0189514 A3 WO0189514 A3 WO 0189514A3
Authority
WO
WIPO (PCT)
Prior art keywords
metal ion
agent
ion chelating
chelating agent
radical scavenging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/002267
Other languages
English (en)
Other versions
WO2001089514A2 (fr
Inventor
David Buell Goodale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0012599A external-priority patent/GB0012599D0/en
Priority claimed from GB0013367A external-priority patent/GB0013367D0/en
Priority to EP01931901A priority Critical patent/EP1289518A2/fr
Priority to CA002408033A priority patent/CA2408033A1/fr
Priority to AU2001258592A priority patent/AU2001258592A1/en
Priority to JP2001585758A priority patent/JP2003534277A/ja
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Priority to MXPA02011531A priority patent/MXPA02011531A/es
Priority to IL15277401A priority patent/IL152774A0/xx
Priority to BR0111094-2A priority patent/BR0111094A/pt
Publication of WO2001089514A2 publication Critical patent/WO2001089514A2/fr
Publication of WO2001089514A3 publication Critical patent/WO2001089514A3/fr
Priority to NO20025628A priority patent/NO20025628L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention a trait à une méthode visant à traiter des patients gravement malades et à augmenter leurs chances de survie. Elle concerne également l'utilisation de compositions pharmaceutiques sédative stériles aux fins de la production d'un médicament destiné à augmenter ces chances de survie. Elle porte, notamment, sur l'utilisation de compositions pharmaceutiques contenant un agent sédatif phagocyte de radical libre (tel que du Propofol) et un agent chélateur d'ions métalliques (tel qu'un édétate) en association avec un diluant ou un excipient acceptable du point de vue pharmaceutique. Cette composition contient, notamment, une émulsion aqueuse dans laquelle le Propofol dissous dans un solvant non miscible dans l'eau est émulsionné avec de l'eau et stabilisé par un tensioactif, laquelle émulsion renferme, en outre, un agent chélateur d'ions métalliques, tel que de l'édétate de disodium.
PCT/GB2001/002267 2000-05-25 2001-05-22 Ameliorations apportees en matiere de survie Ceased WO2001089514A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR0111094-2A BR0111094A (pt) 2000-05-25 2001-05-22 Composição farmacêutica, uso de uma composição farmacêutica estéril, e, método para melhorar a sobrevida em um paciente criticamente doente
IL15277401A IL152774A0 (en) 2000-05-25 2001-05-22 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
CA002408033A CA2408033A1 (fr) 2000-05-25 2001-05-22 Ameliorations apportees en matiere de survie
AU2001258592A AU2001258592A1 (en) 2000-05-25 2001-05-22 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
JP2001585758A JP2003534277A (ja) 2000-05-25 2001-05-22 生存性改善
EP01931901A EP1289518A2 (fr) 2000-05-25 2001-05-22 Ameliorations apportees en matiere de survie
MXPA02011531A MXPA02011531A (es) 2000-05-25 2001-05-22 Beneficio de superviviencia.
NO20025628A NO20025628L (no) 2000-05-25 2002-11-22 Overlevelseshjelp

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0012599A GB0012599D0 (en) 2000-05-25 2000-05-25 Survival benefit
GB0012599.7 2000-05-25
GB0013367.8 2000-06-02
GB0013367A GB0013367D0 (en) 2000-06-02 2000-06-02 Survival benefit

Publications (2)

Publication Number Publication Date
WO2001089514A2 WO2001089514A2 (fr) 2001-11-29
WO2001089514A3 true WO2001089514A3 (fr) 2002-05-16

Family

ID=26244338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/002267 Ceased WO2001089514A2 (fr) 2000-05-25 2001-05-22 Ameliorations apportees en matiere de survie

Country Status (11)

Country Link
EP (1) EP1289518A2 (fr)
JP (1) JP2003534277A (fr)
KR (1) KR20030007686A (fr)
CN (1) CN1217657C (fr)
AU (1) AU2001258592A1 (fr)
BR (1) BR0111094A (fr)
CA (1) CA2408033A1 (fr)
IL (1) IL152774A0 (fr)
MX (1) MXPA02011531A (fr)
NO (1) NO20025628L (fr)
WO (1) WO2001089514A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2470500C (fr) * 2001-12-28 2012-05-15 Guilford Pharmaceuticals, Inc. Formulations pharmaceutiques aqueuses de prodrogues de propofol solubles dans l'eau
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
BR0313060A (pt) 2002-07-29 2005-06-28 Transform Pharmaceuticals Inc Composições farmacêuticas aquosas de 2,6-diisopropilfenol
TW202536885A (zh) * 2024-02-29 2025-09-16 馬雅資訊股份有限公司 用於建立血液透析患者死亡之預測模型的方法、系統、及用於預測血液透析患者死亡的方法、非暫態電腦可讀取儲存媒體

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2298789A (en) * 1994-03-22 1996-09-18 Zeneca Ltd Oil-in-Water pharmaceutical composition containing edetate (EDTA) and preferably propofol(2,6-diisopropylphenol)
WO2000024376A1 (fr) * 1998-10-23 2000-05-04 Abbott Laboratories Composition de propofol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2298789A (en) * 1994-03-22 1996-09-18 Zeneca Ltd Oil-in-Water pharmaceutical composition containing edetate (EDTA) and preferably propofol(2,6-diisopropylphenol)
WO2000024376A1 (fr) * 1998-10-23 2000-05-04 Abbott Laboratories Composition de propofol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D.L.HERR E.A.: "Safety and efficacy of propofol with EDTA when used for sedation of surgical intensive care unit patients", INTENSIVE CARE MEDICINE, vol. 26, no. 4, 2000, pages 452 - 462, XP001052864 *

Also Published As

Publication number Publication date
IL152774A0 (en) 2003-06-24
WO2001089514A2 (fr) 2001-11-29
MXPA02011531A (es) 2003-04-25
EP1289518A2 (fr) 2003-03-12
AU2001258592A1 (en) 2001-12-03
CN1217657C (zh) 2005-09-07
CA2408033A1 (fr) 2001-11-29
JP2003534277A (ja) 2003-11-18
NO20025628D0 (no) 2002-11-22
CN1430511A (zh) 2003-07-16
BR0111094A (pt) 2003-04-08
KR20030007686A (ko) 2003-01-23
NO20025628L (no) 2003-01-16

Similar Documents

Publication Publication Date Title
DE60129134D1 (en) O/w emulsion
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
AP1727A (en) Methods and compositions for treating flaviviruses and pestiviruses.
DE69940015D1 (de) Pharmazeutische zubereitungen enthaltend einen amphoteren emulgator, polyproxylierten cetylalkohol und einen polaren wirkstoff
WO2002056912A3 (fr) Methode de traitement du cancer
RU2009149687A (ru) Фармацевтические композиции и способы лечения сухих кератитов
MXPA02012651A (es) Formulaciones para neutralizacion de toxantes quimicos y biologicos.
HRP20021009B1 (hr) Postupak za pripremu pripravka
MY116758A (en) Preparation of fluorinated polymers.
WO2003020024A3 (fr) Traitement et prevention des infections des plantes
WO2003056062A3 (fr) Derives de polymeres concus pour traiter des metaux
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
FR2833184B1 (fr) Procede de preparation d'une emulsion multiple de type eau/huile/eau
BRPI0409413A (pt) composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável
EP1166778A3 (fr) Utilisation d'un sécrétagogue d'hormone de croissance pour traiter le lupus érythémateux systémique et les maladies intestinales inflammatoires
WO2001089514A3 (fr) Ameliorations apportees en matiere de survie
WO2006039231A3 (fr) Preparations topiques pour le traitement de la depression avec la s-adenosyl methionine
RU2206319C2 (ru) Эмульсия перфторорганических соединений для медицинских целей, способ ее приготовления и способы лечения и профилактики заболеваний с ее использованием
WO2004016243A3 (fr) Methodes d'administration et d'amelioration de l'absorption d'agents pharmaceutiques
MY132819A (en) Pharmaceutical compositions containing n-sulphonylindoline derivatives
BR0009214A (pt) Composições aquosas estáveis contendo umcomposto de silìcio
SE0002354D0 (sv) New formulation
EA200801973A1 (ru) Перфторуглеродная газопереносящая эмульсия для медико-биологических целей, способ ее получения и средство для лечения (варианты)
WO2025144872A3 (fr) Lipides dérivés de nucléosides pour l'administration de médicaments
WO2003024421A3 (fr) Forme posologique de triclosan

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001258592

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002/08857

Country of ref document: ZA

Ref document number: 200208857

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2408033

Country of ref document: CA

Ref document number: 522366

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 152774

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/011531

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020027015890

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018101011

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001931901

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027015890

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001931901

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 2001931901

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 2001931901

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001931901

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001931901

Country of ref document: EP